Open Access Review

Research progress of nanomedicine for tumor immunotherapy

by Xingyi Wan a Mengyan Jiang b  and  Shriya Madan c,* orcid
Beijing Institute of Nanoenergy and Systems, University of Chinese Academy of Sciences, Beijing, China
College of Biological Resources and Environmental Engineering, Beijing University of Agriculture, Beijing, China
University of Maryland, Maryland, USA
Author to whom correspondence should be addressed.
CI  2023, 31; 3(1), 31;
Received: 23 October 2023 / Accepted: 4 December 2023 / Published Online: 28 December 2023


Cancer, a pervasive threat to human health, presents formidable challenges to traditional treatment approaches. Tumor immunotherapy has emerged as a promising strategy for combating malignancies by bolstering the body's immune response to thwart tumor metastasis and recurrence. Nonetheless, the intricacies of tumors, patient heterogeneity, and the presence of tumor-immunosuppressive microenvironments have limited the overall efficacy of immunotherapy, achieving only approximately a 20% success rate. In recent years, nanomaterials have garnered increasing attention in the realm of tumor immunotherapy due to their inherent advantages, such as excellent biocompatibility, precise targeting, and controlled drug release. Nanomaterials empower immunostimulatory molecules and therapeutic agents with the ability to specifically target tumors, amplify drug accumulation at tumor sites, facilitate local immune modulation, alleviate immunosuppressive microenvironments, and thereby enhance the effectiveness of tumor immunotherapy. This review provides an overview of the current state of immunotherapy and offers insights into the ongoing research progress surrounding various nanomaterials aimed at augmenting the efficacy of immunotherapy.

Copyright: © 2023 by Wan, Jiang and Madan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (Creative Commons Attribution 4.0 International License). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Show Figures

Share and Cite

ACS Style
Wan, X.; Jiang, M.; Madan, S. Research progress of nanomedicine for tumor immunotherapy. Cancer Insight, 2024, 3, 31.
AMA Style
Wan X, Jiang M, Madan S. Research progress of nanomedicine for tumor immunotherapy. Cancer Insight; 2024, 3(1):31.
Chicago/Turabian Style
Wan, Xingyi; Jiang, Mengyan; Madan, Shriya 2024. "Research progress of nanomedicine for tumor immunotherapy" Cancer Insight 3, no.1:31.
APA style
Wan, X., Jiang, M., & Madan, S. (2024). Research progress of nanomedicine for tumor immunotherapy. Cancer Insight, 3(1), 31.

Article Metrics

Article Access Statistics


  1. Topalian S L, Weiner G J, Pardoll D M. (2011). Cancer immunotherapy comes of age. J Clin Oncol 29(36), 4828-4836.
  2. Galluzzi L, Vacchelli E, Bravo-san Pedro J M, et al. (2014). Classification of current anticancer immunotherapies. Oncotarget 5(24), 12472-12508.
  3. Rosenberg S A, Restifo N P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348(6230), 62-68.
  4. Parker B S, Rautela J, Hertzog P J. (2016). Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16(3), 131-144.
  5. Rosenberg S A. (2014). IL-2: the first effective immunotherapy for human cancer. J Immunol 192(12), 5451-5458.
  6. Asmana Ningrum R. (2014). Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica (Cairo) 2014, 970315.
  7. Robert C, Schachter J, Long G V, et al. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26), 2521-2532.
  8. Borghaei H, Paz-ares L, Horn L, et al. (2015). Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373(17), 1627-1639.
  9. Ma W J, Gilligan B M, Yuan J D, et al. (2016). Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 9(1), 47.
  10. Ledford H. (2013). Immunotherapy's cancer remit widens. Nature 497(7451), 544.
  11. Cheung AS, Zhang DKY, Koshy ST, Mooney DJ. (2018). Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat Biotechnol 36(2), 160-9.
  12. Lee JY, Kim MK, Nguyen TL, Kim J. (2020). Hollow Mesoporous Silica Nanoparticles with Extra-Large Mesopores for Enhanced Cancer Vaccine. ACS Appl Mater Interfaces 12(31), 34658-66.
  13. Vallhov H, Gabrielsson S, Strùmme M, Scheynius A, Garcia Bennett AE. (2007). Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett 7(12), 3576-82.
  14. Nguyen TL, Choi Y, Kim J. (2019). Mesoporous Silica as a Versatile Platform for Cancer Immunotherapy. Adv Mater 31(34), 1803953.
  15. Yang H, Liu HS, Hou W, Gao JX, Duan Y, Wei D, et al. (2020). An NIR-responsive mesoporous silica nanosystem for synergetic photothermal-immunoenhancement therapy of hepatocellular carcinoma. J Mater Chem B 8(2), 251-9.
  16. Xu C, Nam J, Hong H, Xu Y, Moon JJ. (2019). Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy. ACS Nano 13(10), 12148-61.
  17. Yang G, Xu L, Xu J, Zhang R, Song G, Chao Y, et al. (2018). Smart Nanoreactors for pH-Responsive Tumor Homing, Mitochondria-Targeting, and Enhanced Photodynamic Immunotherapy of Cancer. Nano Letter 18(4), 2475-84.
  18. Yu X, Gao D, Gao L, et al. (2017). Inhibiting metastasis and preventing tumor relapse by triggering host immunity with tumor-targeted photodynamic therapy using photosensitizer-loaded functional nanographenes. ACS Nano 11(10), 10147-10158.
  19. Lebre F, Boland JB, Gouveia P, Gorman AL, Lundahl MLE, R IL, et al. (2020). Pristine graphene induces innate immune training. Nanoscale 12(20), 11192-200.
  20. Ding Z, Luo N, Yue H, Gao Y, Ma G, Wei W. (2020). In vivo immunological response of exposure to PEGylated graphene oxide via intraperitoneal injection. J Mater Chem B 8(31), 6845-56.
  21. Tao Y, Ju E, Ren J, Qu X. (2014). Immunostimulatory oligonucleotides loaded cationic graphene oxide with photothermally enhanced immunogenicity for photothermal/immune cancer therapy. Biomaterials 35(37), 9963-71.
  22. Hulsmans M, Sam F, Nahrendorf M. (2016). Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol 93, 149-55.
  23. Gombozhapova A, Rogovskaya Y, Shurupov V, Rebenkova M, Kzhyshkowska J, Popov SV, et al. (2017). Macrophage activation and polarization in post-infarction cardiac remodeling. J Biomed Sci 24(1), 13.
  24. Wu C, Wang L, Tian Y, Guan X, Liu Q, Li S, et al. (2018). “Triple Punch” Anticancer Strategy Mediated by Near-Infrared Photosensitizer/CpG Oligonucleotides Dual-Dressed and Mitochondria-Targeted Nanographene. ACS Appl Mater Interfaces 10(8), 6942-55.
  25. Wang BH, AN JY, Zhang H F, et al. (2018). Personalized cancer immunotherapy via transporting endogenous tumor antigens to lymph nodes mediated by nano Fe3O4 Small. 14(38), e1801372.
  26. Zhang D, Wu TT, Qin XY, et al. (2019). Intracellularly generated immunological gold nanoparticles for combinatorial photothermal therapy and immunotherapy against tumor. Nano Lett 19(9), 6635-6646.
  27. ZOGLMEIER C, BAUER H, NOERENBERG D, et al. (2011). CpG blocks immunosuppression by myeloid-derived suppressor cells in tumorbearing mice. Clin Cancer Res 17(7), 1765-1775.
  28. Li L, Yang S, Song L, et al. (2018). An endogenous vaccine based on fluorophores and multivalent immunoadjuvants regulates tumor microenvironment for synergistic photothermal and immunotherapy. Theranostics 8(3), 860-873.
  29. Park J, Wrzesinski S H, Stern E, et al. 2012). Combination delivery of TGF- β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat Mater 11(10), 895-905.
  30. Zhou P, Qin J Q, Zhou C, et al. (2019). Multifunctional nanoparticles based on a polymeric copper Chelator for combination treatment of metastatic breast cancer. Biomaterials 195, 86-99.
  31. Chen Q, Chen J, Yang Z, et al. (2019). Nanoparticle-enhanced radiotherapy to trigger robust cancer immunotherapy. Adv Mater 31(10), e1802228.
  32. Su Z W, Xiao Z C, Wang Y, et al. (2020). Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dualsensitive micelles for enhanced tumor chemoimmunotherapy. Small 16(7), e1906832.
  33. Shae D, Becker K W, Christov P, et al. (2019). Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. Nat Nanotechnol 14(3), 269-278.
  34. Chao Y, Chen Q, Liu Z, et al. (2020). Smart injectable hydrogels for cancer immunotherapy. Adv Funct Mater 30(2), 1902785.
  35. Jin H L, Wan C, Zou Z W, et al. (2018). Tumor ablation and therapeutic immunity induction by an injectable peptide hydrogel. ACS Nano 12(4), 3295-3310.
  36. Bencherif S A, Warren Sands R, ALI O A, et al. (2015). Injectable cryogel-based whole-cell cancer vaccines. Nat Commun 6, 7556.
  37. Wang H M, Luo Z C, Wang Y Z, et al. (2016). Enzyme-catalyzed formation of supramolecular hydrogels as promising vaccine adjuvants. Adv Funct Mater 26(11), 1822-1829.
  38. Luo Z C, Wu Q J, Yang C B, et al. (2017). A powerful CD8+ T-cell stimulating D-Tetra-peptide hydrogel as a very promising vaccine adjuvant. Adv Mater 29(5), 1601776.
  39. Wang Z Y, Shang Y N, Tan Z Q, et al. (2020). A supramolecular protein chaperone for vaccine delivery. Theranostics 10(2), 657-670.
  40. Sheth T, Seshadri S, Prileszky T, et al. (2020). Multiple nanoemulsions. Nat Rev Mater 5(3), 214-228.
  41. Jia L, Pang M H, Fan M, et al. (2020). A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors. Theranostics 10(22), 9956-9969.
  42. Hu C M, Zhang L, ARYAL S, et al. (2011). Erythrocyte membranecamouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci U S 108(27), 10980-10985.
  43. Kroll A V, Fang R H, JIANG Y, et al. (2017). Nanoparticulate delivery of cancer cell membrane elicits multiantigenic antitumor immunity. Adv Mater 29(47), 1703969.
  44. Deng G J, Sun Z H, Li S P, et al. (2018). Cell-membrane immunotherapy based on natural killer cell membrane coated nanoparticles for the effective inhibition of primary and abscopal tumor growth. ACS Nano 12(12), 12096-12108.
  45. Cao H Q, Dan Z L, He X Y, et al. (2016). Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10(8), 7738-7748.
  46. Li W, Yang J, Luo L, et al. (2019). Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun 10(1), 3349.
  47. Wu C, Guan X, Xu J, et al. (2019). Highly efficient cascading synergy of cancer photo-immunotherapy enabled by engineered graphene quantum dots/photosensitizer/CpG oligonucleotides hybrid nanotheranostics. Biomaterials 205, 106-119.
  48. Barillet S, Fattal E, Mura S, et al. (2019). Immunotoxicity of poly (lactic-co-glycolic acid) nanoparticles: influence of surface properties on dendritic cell activation. Nanotoxicology 13(5), 606-622.
  49. Steenblock E R, Fahmy T M. (2008). A comprehensive platform for Ex Vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol Ther 16(4), 765-772.
  50. Freeman G J, Sharpe A H, Keir M E, et al. (2008). PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26(1), 677-704.
  51. Wang J C, Sun X, Ma Q, et al. (2018). Metformin's antitumour and anti-angiogenic activities are mediated by skewing macrophage polarization. J Cell Mol Med 22(8), 3825-3836.
  52. Ledo A M, Sasso M S, Bronte V, et al. (2019). Co-delivery of RNAi and chemokine by polyarginine nanocapsules enables the modulation of myeloid-derived suppressor cells. J Controlled Release 295, 60-73.
  53. Burkert S C, Shurin G V, White D L, et al. (2018). Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups. Nanoscale 10(37), 17990-18000.
  54. Lpez-Soto, Alejandro, Gonzalez S, Smyth M J, et al. (2017). Control of metastasis by NK Cells. Cancer Cell 32(2), 135-154.
  55. Ji T, Lang J, Ning B, et al. (2019). Enhanced natural killer cell immunotherapy by rationally assembling Fc fragments of antibodies onto tumor membranes. Adv Mater 31(6), e1804395.